26th week of 2022 patent applcation highlights part 31 |
Patent application number | Title | Published |
20220204922 | PURIFIED FISH PROTEASES WITH HIGH SPECIFIC ACTIVITIES AND ITS PROCESS OF PRODUCTION - The invention concerns a process for the preparation of fish proteases from fish viscera, preferably from cod ( | 2022-06-30 |
20220204923 | CHEMICALLY DEFINED MEDIUM FOR DIFFERENTIATION OF MUSCLE STEM CELLS IN VITRO - A chemically defined medium for differentiation of muscle stem cells in vitro, namely a serum-free, more efficient and inexpensive chemically defined medium for inducing differentiation of muscle stem cells in vitro. Compared with an existing general muscle stem cell differentiation medium, using the chemically defined medium can increase the relative expression of myogenin genes by 4.48 times on the 2 | 2022-06-30 |
20220204924 | ENGINEERED ENDOTHELIAL CELLS EXPRESSING AN ETS TRANSCRIPTION FACTOR - In some aspects the present invention relates to engineered endothelial cells, such as E4ORF1+ ETV2+ engineered endothelial cells. In other aspects the present invention relates to methods of making such engineered endothelial cells, and methods of using such engineered endothelial cells, for example in co-culture applications. | 2022-06-30 |
20220204925 | GENERATION OF NOREPINEPHRINE NEURONS FROM HUMAN STEM CELLS - Methods for obtaining populations of norepinephrine (NE) neuronal progenitor cells and creating enriched populations of NE neurons are provided herein. Also provided herein are methods for obtaining genetically modified NE neurons expressing a NE sensor or a TH-reporter, and methods for using NE neurons obtained according to the methods of this disclosure. | 2022-06-30 |
20220204926 | SOX9-INDUCED OLIGODENDROCYTE PROGENITOR CELLS - Provided herein is a differentiation agent that consist essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSCs). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes. | 2022-06-30 |
20220204927 | 4D PRINTING SMART CULTURE SUBSTRATE FOR CELL GROWTH - Disclosed herein is a 4D printed programmable culture substrate with the self-morphing ability to accommodate the change in morphology of stem cells during differentiation. The 4D printed culture substrate includes a shape memory polymer that is configured for transformation from a first topographical shape to a second topographical shape during a predetermined time period in response to a stimulus, such as temperature. The first topographical shape may include micro-wells and the second topographical shape may include microgrooves, which can accommodate the growth and differentiation of neural stem cells. | 2022-06-30 |
20220204928 | EXTRACELLULAR VESICLES DERIVED FROM ACTIVATED CAR-T CELLS - The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) specifically activated with an antigen to which the CAR bind specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular the present invention exemplifies EVs derived from activated T-cells expressing CAR that bind specifically to HER2 cancer antigen, pharmaceutical composition comprising these EVs and their use in treating a cancer overexpressing HER2, such as ovarian cancer and breast cancer. | 2022-06-30 |
20220204929 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) - The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells. | 2022-06-30 |
20220204930 | PROSTATE CANCER CHIMERIC ANTIGEN RECEPTORS - Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the anti-PMCA antigen binding domains disclosed herein. SynNotch receptors that comprise an anti-PSCA binding domain Provided are polynucleotides encoding antibodies, fragments thereof, CARs, T cell receptors (TCR) and SynNotch receptors. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment. | 2022-06-30 |
20220204931 | BEAD-FREE EX-VIVO EXPANSION OF HUMAN REGULATORY T CELLS - The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in adoptive cell therapy. In particular, the present disclosure relates to simplified approaches for the expansion of Tregs ex vivo. Tregs produced in this way are suitable for use in various immunotherapy regimens. | 2022-06-30 |
20220204932 | PROCESSES FOR GENERATING TIL PRODUCTS ENRICHED FOR TUMOR ANTIGEN-SPECIFIC T-CELLS - The present invention provides improved and/or shortened processes and methods for reprogramming TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy. Such reprogrammed TILs find use in therapeutic treatment regimens. | 2022-06-30 |
20220204933 | METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENS - Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity; and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material. | 2022-06-30 |
20220204934 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS - The disclosure features methods and compositions for differentiating stem cells into hematopoietic stem and progenitor cells (HSPC) and/or Natural Killer (NK) cells. The methods and compositions described herein are used to differentiate stem or progenitor cells having at least one gene-edit that is maintained in the differentiated cell. Also provided are differentiated cells produced using the methods and compositions described herein for therapeutic applications. | 2022-06-30 |
20220204935 | MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF - Hematopoeitic stem/progenitor cells (HSPC) and/or non-T effector cells are modified to express an extracellular component including a tag cassette. The tag cassette can be used to activate, promote proliferation of, detect, enrich, isolate, track, deplete and/or eliminate modified cells. The cells can also be modified to express a binding domain. | 2022-06-30 |
20220204936 | NON-FIBROUS FILM AND CELL SHEET - A non-fibrous film of which the composition includes a collagen and a polyester polymer is provided. A content of the polyester polymer in the non-fibrous film is 1-60 wt %. Moreover, the non-fibrous film has a swelling rate of 1-200 μm/hour or a swelling proportion per unit time of 0.1-2%/hour in an aqueous liquid. | 2022-06-30 |
20220204937 | Force Stimulation Loading Device and Working Method Thereof - The invention provides a force stimulation loading device and a working method thereof, the force stimulation loading device comprises: a containing body, a stretching mechanism and a twisting mechanism; the containing body is suitable for containing a gel encapsulating cardiomyocytes, and is made of a non-rigid material; the stretching mechanism is suitable for stretching or squeezing the containing body from opposite sides of the containing body to apply a stretching or squeezing force to the gel; the twisting mechanism is suitable for twisting the containing body to apply a twisting stress to the gel; the force stimulation loading device of the present invention is capable of simultaneously applying the stretching or squeezing force and the twisting stress to the gel encapsulating the cardiomyocytes through the stretching mechanism and the twisting mechanism, that is, applying the stretching or squeezing force and the twisting stress to the cardiomyocytes at the same time. | 2022-06-30 |
20220204938 | PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS - Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods. | 2022-06-30 |
20220204939 | COSMETIC COMPOSITION COMPRISING CULTURE SOLUTION OF MESENCHYMAL STEM CELLS CULTURED IN HPL-CONTAINING MEDIUM - The present invention relates to: a method for preparing a stem cell culture solution which contains growth factors and cytokines and is obtained by culturing, in a serum-free medium, mesenchymal stem cells cultured in a medium containing human platelet lysates (hPLs); and a cosmetic composition using the stem cell culture solution. When the method for preparing a mesenchymal stem cell culture solution obtained from mesenchymal stem cells cultured in an hPL-containing medium is used, it is possible to obtain a mesenchymal stem cell culture solution which has a higher amount of cytokines and growth factors than that of a mesenchymal stem cell culture solution obtained from mesenchymal stem cells cultured in an FBS-containing medium, and has excellent efficacy in the promotion of human dermal fibroblast proliferation, collagen synthesis, elastin synthesis, inhibition of melanin synthesis, and hair growth. The mesenchymal stem cell culture solution can be used to produce cosmetics having effects of skin regeneration, wrinkle improvement, skin elasticity enhancement, skin whitening, and hair growth, and thus can be widely used in the cosmetic field and the pharmaceutical industry. | 2022-06-30 |
20220204940 | UNIVERSAL DONOR CELLS - Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor. | 2022-06-30 |
20220204941 | Engineered Intestinal Tissue and Uses Thereof - Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model. | 2022-06-30 |
20220204942 | Engineered Intestinal Tissue and Uses Thereof - Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model. | 2022-06-30 |
20220204943 | CELL CULTURE SYSTEMS, METHODS AND USES THEREOF - The present disclosure provides a surface coating comprising a hydrophilic polymer and polyelectrolyte multilayers. Also provided is a cell culture system comprising a cell culture article having a surface coated with the surface coating. Uses and methods of preparing the surface coatings and systems are provided as well. | 2022-06-30 |
20220204944 | CELL CULTURE SUBSTRATES, METHODS AND USES THEREOF - The present disclosure provides a substrate for cell culture. Systems comprising the substrate, and methods for using and manufacturing the substrate are also disclosed herein. | 2022-06-30 |
20220204945 | AAV PRODUCTION USING SUSPENSION ADAPTED CELLS - Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells. | 2022-06-30 |
20220204946 | MODIFIED ENVELOPE GLYCOPROTEINS FOR RETROVIRIDAE VIRAL VECTOR PSEUDOTYPING AND PROCESS FOR OBTAINING IT - The present invention describes the development of a modified envelope glycoproteins to pseudo-type viruses of the retroviridae family. These are derived from Murine leukaemia virus amphotropic, Gibbon Ape leukaemia virus and feline endogenous virus envelopes. | 2022-06-30 |
20220204947 | GLYCEROL FREE ETHANOL PRODUCTION - The invention relates to a recombinant cell, preferably a yeast cell comprising: a) one or more heterologous genes encoding a glycerol dehydrogenase activity; b) one or more genes encoding a dihydroxyacetone kinase (E.C. 2.7.1.28 and/or E.C. 2.7.1.29); c) one or more heterologous genes encoding a ribulose-1,5-biphosphate carboxylase oxygenase (EC 4.1.1.39, RuBisCO); and d) one or more heterologous genes encoding a phosphoribulokinase (EC 2.7.1.19, PRK); and optionally e) one or more heterologous genes encoding for a glycerol transporter. This cell can be used for the production of ethanol and advantageously produces little or no glycerol. | 2022-06-30 |
20220204948 | MACHINE LEARNING GENE MINING METHOD AND PHOSPHINOTHRICIN DEHYDROGENASE MUTANT FOR AMINO TRANSLOCATION - Disclosed are a machine learning gene mining method and a phosphinothricin dehydrogenase mutant for amino translocation. The phosphinothricin dehydrogenase mutant for amino translocation is obtained by mutation of a wild-type phosphinothricin dehydrogenase with an amino acid sequence as shown in SEQ ID No.2 at one of the following sites: (1) E263D-K134R-H96A-R290V; (2) E263D-K134R-H96A; (3) E263D-K134R; (4) E263D; (5) E263N; (6) E263C; and (7) E263G. The present invention utilizes the site-saturation mutagenesis technology to mutate a phosphinothricin dehydrogenase gene as shown in SEQ ID No. 1, finds that the 263rd, 134th, 290th and 290th positions are the key sites affecting enzyme activity and stereoselectivity, and obtains a mutant with enzyme activity and ee value much higher than those of the parent phosphinothricin dehydrogenase. | 2022-06-30 |
20220204949 | GENE MINING METHOD COMBINING FUNCTIONAL SEQUENCE AND STRUCTURE SIMULATION, NADH-PREFERRING PHOSPHINOTHRICIN DEHYDROGENASE MUTANT AND APPLICATION THEREOF - Disclosed are a gene mining method combining functional sequence and structure simulation, an NADH-preferring phosphinothricin dehydrogenase mutant and an application thereof. The gene mining method comprises the following steps: (1) analyzing a characteristic sequence which an NADH-type glutamate dehydrogenase should have; (2) searching a gene library based on the characteristic sequence; (3) performing clustering analysis and protein structure simulation on genes obtained by the searching; (4) selecting genes that feature high gene aggregation and a protein structure similar to that of the known phosphinothricin dehydrogenase as candidate genes. A wild-type phosphinothricin dehydrogenase with an amino acid sequence as set forth in SEQ ID No.2 derived from Lysinibacillus composti is obtained through the gene mining, and then mutated, and an NADH-preferring phosphinothricin dehydrogenase mutant is screened out, which has a mutation site selected from one of the following: (1) A144G-V375F-M91A; (2) A144G-V345A-M91A; (3) A144G. This mutant enzyme can be used for catalytic reaction with an inexpensive coenzyme NAD. | 2022-06-30 |
20220204950 | A NEW TYPE OF ENZYME COMPOSITION - The present disclosure relates to a tyrosine hydroxylase (TH) variant lacking 60 to 120 amino acid residues at the N terminus, and a pharmaceutical composition comprising the TH variant lacking 60 to 120 amino acid residues at the N terminus and the aromatic L-amino acid decarboxylase (AADC). The present disclosure further relates to a nucleotide construct, a vector plasmid, a cell or a virus comprising the TH variant or the pharmaceutical composition, as well as use of the virus in the manufacture of a medicament for treating neurodegenerative diseases (e.g., Parkinson's Disease). | 2022-06-30 |
20220204951 | ENGINEERED GLUCOSYLTRANSFERASES - Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes synthesize insoluble alpha-glucan products having decreased molecular weight. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce insoluble alpha-glucan. | 2022-06-30 |
20220204952 | PRODUCTION OF CATALYTICALLY ACTIVE TYPE I SULFATASE - The present disclosure provides methods for producing activated type I sulfatases, or functional fragments thereof, using Formylglycine Generating Enzymes (FGEs). Also featured by the disclosure are recombinant fungal (e.g., | 2022-06-30 |
20220204953 | Mutant of Acid Phosphatase and Application Thereof - Disclosed is a mutant of acid phosphatase and an application thereof, belonging to the technical field of biological engineering. The disclosure provides a mutant of acid phosphatase PaAPase | 2022-06-30 |
20220204954 | ENGINEERED CAS9 WITH BROADENED DNA TARGETING RANGE - The disclosure provides variant Staphylococcus aureus Cas9 (SaCas9) proteins with altered specificity for protospacer adjacent motif (PAM) sequences. The disclosure also is directed to CRISPR/Cas9 systems and methods of altering a genomic DNA sequence using the variant SaCas9 protein. Methods of generating variant Cas9 proteins with altered PAM specificity are also disclosed. | 2022-06-30 |
20220204955 | TARGET-SPECIFIC CRISPR MUTANT - The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc. | 2022-06-30 |
20220204956 | Additional Endoglucanase Variants and Methods - The invention is directed to novel variant endoglucanases and their use thereof. | 2022-06-30 |
20220204957 | METHOD OF PURIFYING BOTULINUM TOXIN - Disclosed is a method of purifying a botulinum toxin comprising (a) pre-treating a culture solution containing a botulinum toxin, (b) purifying the pre-treated botulinum toxin using cation exchange chromatography, (c) purifying the botulinum toxin using hydrophobic chromatography, and (d) purifying the botulinum toxin using anion exchange chromatography. The method is capable of purifying a botulinum toxin with high purity and activity and is thus useful for botulinum toxin production. | 2022-06-30 |
20220204958 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use. | 2022-06-30 |
20220204959 | COMPOSITIONS AND METHODS COMPRISING PROTEASE VARIANTS - The present invention provides protease variants, compositions comprising protease variants, and methods of using such protease variants and compositions. | 2022-06-30 |
20220204960 | PROTEASES HAVING IMPROVED ENZYME STABILITY IN WASHING AND CLEANING AGENTS III - Proteases may include an amino acid sequence having at least 70% sequence identity with the amino acid sequence given in SEQ ID NO: 1 over its entire length and, in each case based on the numbering according to SEQ ID NO: 1, may include (i) amino acid substitutions, such as selected from amino acid substitutions 9T, 144K, 252T and 271E, at positions corresponding to positions 9, 144, 252 and 271, and (ii) at least one additional amino acid substitution at least at one of the positions corresponding to positions 53, 120, 131, 149, 159, 162, 166, 172, 189, 192, 211, 215, 217, 224 and 274. Production and use of said proteases are described herein. Proteases of this kind demonstrate very good stability with a good cleaning performance. | 2022-06-30 |
20220204961 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES - Modified DDAH polypeptides and their uses thereof are provided. Exemplary embodiments provide DDAH polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and/or linkage to other biologically active molecules including other DDAH polypeptides, as well as PKEM. Additionally, use of said DDAH polypeptides for treatment of disease, such as heart failure or renal disease, is also provided. | 2022-06-30 |
20220204962 | PLANT UREASE-CONTAINING SOIL SOLIDIFICATION AGENT AND ZERO-WASTE PRODUCTION PROCESS THEREOF - The present invention belongs to the technical field of rock and soil reinforcement, and specifically relates to a plant urease-containing soil solidification agent and a zero-waste production process thereof. A crudely-purified plant urease solution includes a large amount of irrelevant proteins, which seriously affects the treatment effect of the soil solidification agent, makes it impossible to achieve an expected construction purpose, and also causes serious waste and environmental pollution. In the present invention, a common plant urease extraction method on the market is optimized to significantly reduce a protein concentration in a plant urease solution, greatly improve the infiltration performance of a plant urease-containing soil solidification agent, and broaden an application range of such a soil solidification agent. | 2022-06-30 |
20220204963 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. | 2022-06-30 |
20220204964 | SYSTEMS AND METHODS FOR LIVING SILK ARTICLES - A method of making silk articles including preparing a silk fibroin solution including silk fibroin and microalgae, and introducing the silk fibroin solution into a solvent bath including a crosslinking agent. The method can incorporate 3D printing techniques to allow for easy fabrication of the articles into various forms. The silk articles can provide a cell-friendly matrix that allows 3D encapsulation of microalgae while maintaining normal cell proliferation and functions for an extended period of time. | 2022-06-30 |
20220204965 | METHOD FOR CONSTRUCTING TREHALOSE MULTI-ENZYME COMPLEX IN VITRO MEDIATED BY ARTIFICIAL SCAFFOLD PROTEIN - The present disclosure relates to a method for constructing a trehalose polyenzyme complex in vitro by mediation of an artificial scaffold protein, which mainly comprises the following steps: constructing a recombinant bacterium WB800n-ScafCCR for self-assembled scaffold protein module; constructing a recombinant bacterium WB800n-P43-phoD-treY-Ccdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-treZ-Ctdoc for self-assembled catalytic module; constructing a recombinant bacterium WB800n-P43-phoD-cgt-Rfdoc for self-assembled catalytic module; secretorily expressing the recombinant bacteria and self-assembling in vitro to obtain a recombinant trehalose multi-enzyme complex. The trehalose multi-enzyme complex constructed by the method of the present disclosure has a higher catalytic efficiency in preparing trehalose than that of mixed free enzymes, and the method can be used for production of high quality trehalose after immobilization with cellulose microspheres. | 2022-06-30 |
20220204966 | PROBIOTIC STRAINS HAVING INCREASED STORAGE STABILITY - Evolved strains of | 2022-06-30 |
20220204967 | METHODS FOR EXTRACTING BIOACTIVE SMALL RNAS FROM PLANTS AND MUSHROOMS - The present invention refers to a method for isolating a fraction enriched of small RNA molecules from a fungal or plant sample. | 2022-06-30 |
20220204968 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS - The present invention relates to a lysis, binding and/or wash reagent for isolating and/or purifying nucleic acids and a method for isolating and/or purifying nucleic acids. | 2022-06-30 |
20220204969 | COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLUX CONTROL USING SYNTHETIC METABOLIC VALVES - This invention relates to metabolically engineered microorganisms, such as bacterial and or fungal strains, and bioprocesses utilizing such strains. These strains enable the dynamic control of metabolic pathways, which can be used to optimize production. Dynamic control over metabolism is accomplished via a combination of methodologies including but not limited to transcriptional silencing and controlled enzyme proteolysis. These microbial strains are utilized in a multi-stage bioprocess encompassing at least two stages, the first stage in which organisms are grown and metabolism can be optimized for microbial growth and at least one other stage in which growth can be slowed or stopped, and dynamic changes can be made to metabolism to improve the production of desired product, such as a chemical or fuel. | 2022-06-30 |
20220204970 | POLYVALENT GUIDE RNAS FOR CRISPR ANTIVIRALS - Generally, the present disclosure is directed to methods for gRNA design and products thereof that can be used as antivirals in which the produced gRNAs can be tolerant to polymorphisms across clinical strains and/or adapted for activity at multiple viral sites. Aspects of example gRNAs can also include reduced interactions with the human genome or transcriptome. | 2022-06-30 |
20220204971 | Compositions and Methods for Inhibiting Cancers and Viruses - The present invention relates to compositions comprising isolated, single stranded RNA molecules and pharmaceutically acceptable carriers suitable for injection. The present invention relates to methods for stimulating an immune response and treating tumors. The present invention further relates to kits comprising a cancer vaccine and compositions of the present invention for use as an adjuvant to cancer vaccines. | 2022-06-30 |
20220204972 | Antisense oligonucleotides for the treatment of Stargardt disease - The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease. | 2022-06-30 |
20220204973 | Antisense Oligonucleotide for Targeting Progranulin - The present invention relates to oligonucleotides which alter the splicing pattern of progranulin in cells, and their use in the treatment of neurological disorders. | 2022-06-30 |
20220204974 | RAAV-BASED COMPOSITIONS AND METHODS - The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency). | 2022-06-30 |
20220204975 | SYSTEM FOR GENOME EDITING - The present specification provides compositions and methods that are capable of directly installing an insertion or deletion of a given nucleotide at a specified genetic locus. The compositions and methods involve the novel combination of the use an engineered RNA enzyme (i.e., “ribozyme”) that is capable of site-specifically inserting or deleting a single nucleotide at a genetic locus and the use of a nucleic acid programmable DNA binding protein (napDNAbp) (e.g., Cas9) to target the engineered ribozyme to a specified genetic locus, thereby allowing for the direct installation of an insertion of deletion at the specified genetic locus by the engineered ribozyme. | 2022-06-30 |
20220204976 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use - The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC. | 2022-06-30 |
20220204977 | Gold Optimized CAR T-cells - Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell. | 2022-06-30 |
20220204978 | PROTEIN TRANSLATIONAL CONTROL - Provided herein ar compositions and methods for regulating protein translation. The compositions include a cap-conjugated oligonucleotide comprising an m7G cap or a variant or analog thereof conjugated to an oligonucleotide, wherein the oligonucleotide is capable of specifically hybridizing with a target sequence in an RNA molecule. The disclosure further provides methods of regulating translation of an mRNA in a cell, the method comprising contacting the cell with a cap-conjugated oligonucleotide comprising an m7G cap or a variant or analog thereof conjugated to an oligonucleotide, wherein the oligonucleotide comprises a sequence capable of specifically hybridizing with a target sequence in an RNA molecule. | 2022-06-30 |
20220204979 | METHODS FOR PRODUCING BIOCHEMICALS USING ENZYME GENES DERIVED FROM A STRAIN OF BREVUNDIMONAS, AND COMPOSITIONS MADE THEREBY - A crtW gene from a strain of Brevundimonas is disclosed that encodes a novel ketolase for carotenoid synthesis. An exemplary synthetic operon containing additional relevant carotenoid gene sequences is also provided, where the expression of the synthetic operon is used to produce ketocarotenoids. Suitable DNA expression constructs derived from these sequences are inserted into an expression host for expression. The expression product is a ketolase enzyme that is operable for transforming beta-carotene into canthaxanthin and astaxanthin. | 2022-06-30 |
20220204980 | RESTORER PLANTS - Hybrid cereals are described which are obtained by restoring the pollen fertility for the Pampa cytoplasmic male sterility (P-CMS) and which are characterized by a reduced linkage drag. Plants are provided, in particular rye, which, as the male pollen parent, are capable of restoring the pollen fertility for the P-CMS. Furthermore, the nucleic acid molecule which carries the necessary information for restoring the P-CMS, DNA and vectors which contain such a nucleic acid molecule, corresponding host cells as well as a protein which can be encoded by the nucleic acid molecule and antibodies directed against it are also described. Furthermore, methods for the production of corresponding hybrid plants and transgenic plants are provided. | 2022-06-30 |
20220204981 | COMPOSITIONS AND METHODS FOR PRODUCING TOBACCO PLANTS AND PRODUCTS HAVING ALTERED ALKALOID LEVELS WITH DESIRABLE LEAF QUALITY - The present disclosure includes methods and compositions for improving leaf quality in low-alkaloid tobacco plants, e.g., by combining inducible promoters and non-coding RNAs for suppression of an ornithine decarboxylase (ODC) gene. Also provided are low alkaloid tobacco plants with normal, suppressed, or otherwise altered polyamine levels. Further provided are tobacco plants with altered total alkaloid, nicotine levels, commercially acceptable leaf grade, their development via breeding or transgenic approaches, and production of tobacco products from these tobacco plants. | 2022-06-30 |
20220204982 | TRANSGENIC PLANTS WITH ENGINEERED REDOX SENSITIVE MODULATION OF PHOTOSYNTHETIC ANTENNA COMPLEX PIGMENTS AND METHODS FOR MAKING THE SAME - Embodiments of the present invention provide for a transgenic plan, methods of making and DNA contructs for use in the transgenic plant which transgenic plant is capable of modulating its photosynthetic antenna complex composition in response to increases or decreases in light intensity by modulation of the ratio of chlorophyll a to chlorophyll b such that there is an increase in the Chl a/b ratio at high light intensity and a decrease in the Chl a/b ratio at low light intensity versus wild-type plants grown in the same conditions. | 2022-06-30 |
20220204983 | BRASSICA ROD1 GENE SEQUENCES AND USES THEREOF - The present invention relates to | 2022-06-30 |
20220204984 | METHODS AND COMPOSITIONS FOR MODIFYING PHENOTYPES OF PLANTS EXPRESSING FATTY ACID TRANSGENES AND REDUCED EXPRESSION OF BADC GENES - Compositions that are plants, seeds or crops that have a combination of defective BADC genes and genes for making hydroxy fatty acids produced normal levels of oil containing specialty fatty acids, and exhibited an increases in total oil accumulation, increase in absolute hydroxy (specialized) fatty acid accumulation per seed and/or per plant and/or per unit land area. Defective BADC genes and genes for synthesizing hydroxy fatty acids are combined to produce specialized fatty acids without substantially slowing production of endogenous fatty acids. Methods are also described for increasing production of unusual fatty acids and increasing total fatty acid levels in plants by a mechanism involving combining defective BADC genes and genes for making hydroxy fatty acids to produce steady or increased levels of oil containing the increased specialty products as described herein. | 2022-06-30 |
20220204985 | COMPOSITION FOR PROMOTING PLANT GROWTH COMPRISING YXAL PROTEIN OR HOMOLOGOUS PROTEIN THEREOF, AND METHOD FOR MASS PRODUCTION OF YXAL PROTEIN - The present disclosure relates to a composition for promoting plant growth containing an YxaL protein and a method for mass-producing an YxaL protein. The YxaL protein may be expressed constitutively and in large amounts in a recombinant transformed cell line. When the YxaL protein is applied to seed soaking treatment, root development is improved, and the expression of plant genes involved in root growth is improved in favor of plant growth. Thus, the YxaL protein may be effectively used to promote plant growth. | 2022-06-30 |
20220204986 | CYTOPLASMIC MALE STERILE PLANT OF GENUS LACTUCA HAVING IMPROVED LOW TEMPERATURE GROWTH ABILITY - A cytoplasmic male sterile plant of the genus | 2022-06-30 |
20220204987 | DROUGHT RESISTANCE MULTIGENE CONSTRUCT - The present invention relates to a polygenic DNA construct consisting of three abiotic stress tolerance genes, separated by nucleic acids encoding FMDV 2A peptides under the control of a stress inducible promoter. The stable insertion of the construct into plants confers drought tolerance to the plants. The invention also provides for vectors, host cells, transgenic plants and transgenic seeds containing the construct. | 2022-06-30 |
20220204988 | PROMOTER SEQUENCE AND RELATED PRODUCTS AND USES THEREOF - The present disclosure provides ubiquitous short promoter elements capable of driving gene expression in multiple mammalian cell types of medical interest. Expression vectors incorporating the promoters are disclosed herein. Viral vectors, in particular, AAV vectors with capacity for larger transgenes than are possible with conventional promoters are disclosed herein. Methods of enhancing gene expression are disclosed herein. | 2022-06-30 |
20220204989 | TRIPLE HELIX TERMINATOR FOR EFFICIENT RNA TRANS-SPLICING - A nucleic acid trans-splicing molecule is provided that can replace an exon in a targeted mammalian ocular gene carrying a defect or mutation causing an ocular disease with an exon having the naturally-occurring sequence without the defect or mutation. The trans-splicing molecule includes a 3′ transcription terminator domain which enhances the efficiency of trans-splicing. The 3′ TTD comprises a triple helix domain and a tRNA-like domain. | 2022-06-30 |
20220204990 | NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME - Provided herein are novel AAV capsids and rAAV comprising the same. In one embodiment, vectors employing a novel AAV capsid show increased transduction of a selected target tissue as compared to a prior art AAV. | 2022-06-30 |
20220204991 | Adeno-Associated Virus Compositions for ARSA Gene Transfer and Methods of Use Thereof - Provided herein are adeno-associated virus (AAV) compositions that can express an arylsulfatase A (ARSA) polypeptide in a cell, thereby restoring the ARSA gene function. Also provided are methods of using the AAV compositions, and packaging systems for making the AAV compositions. | 2022-06-30 |
20220204992 | RECOMBINANT ORF VIRUS VECTOR - A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene. | 2022-06-30 |
20220204993 | Compositions And Methods For Viral Delivery Of Neoepitopes And Uses Thereof - Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor. | 2022-06-30 |
20220204994 | METHODS OF PREPARING POPULATIONS OF GENETICALLY-MODIFIED IMMUNE CELLS - The present disclosure provides methods for preparing a population of genetically-modified immune cells. The methods include contacting a population of immune cells with lipid nanoparticles in the presence of an apolipoprotein. The lipid nanoparticles include mRNA encoding an engineered nuclease having specificity for a recognition sequence in the genome of the immune cells. The mRNA is delivered into the immune cells and the engineered nuclease is expressed, generating a cleavage site at the recognition sequence. Further provided are populations of genetic ally-modified immune cells produced according to the disclosed methods, pharmaceutical compositions containing such cells, and methods of treating diseases with the genetically-modified immune cells. | 2022-06-30 |
20220204995 | NON-DISRUPTIVE GENE TARGETING - Compositions and methods are provided for integrating one or more genes of interest into cellular DNA without substantially disrupting the expression of the gene at the locus of integration, i.e., the target locus. These compositions and methods are useful in any in vitro or in vivo application in which it is desirable to express a gene of interest in the same spatially and temporally restricted pattern as that of a gene at a target locus while maintaining the expression of the gene at the target locus, for example, to treat disease, in the production of genetically modified organisms in agriculture, in the large scale production of proteins by cells for therapeutic, diagnostic, or research purposes, in the induction of iPS cells for therapeutic, diagnostic, or research purposes, in biological research, etc. Reagents, devices and kits thereof that find use in practicing the subject methods are also provided. | 2022-06-30 |
20220204996 | PHOTOSYSTEM I-HYDROGENASE CHIMERAS FOR HYDROGEN PRODUCTION - Provided herein, in some embodiments, are engineered cells and use of the same for increased hydrogen production. In particular, provided herein are genetically engineered cells comprising a polynucleotide encoding a fusion protein comprising a photosystem I (PSI) protein and an algal hydrogenase, as well as methods for producing such genetically engineered cells. Also provided herein are methods for increasing hydrogen (H | 2022-06-30 |
20220204997 | ETHANOL - The present disclosure provides a novel and practical alcohol and derivatives thereof which have more industrial value than existing petrochemical raw materials. The present disclosure further provides ethanol, characterized in that a peak in gas chromatography measured by gas chromatograph mass spectrometry (GC/MS) has at least one peak with a retention time selected from (A) a peak of 5 minutes 25 seconds to 5 minutes 35 seconds and two peaks of 2 minutes 55 seconds to 3 minutes 5 seconds; (B) a peak of 12 minutes 30 seconds to 12 minutes 40 seconds; (C) a peak of 6 minutes 36 seconds to 6 minutes 45 seconds; and (D) a peak of 15 minutes 00 seconds to 15 minutes 15 seconds. | 2022-06-30 |
20220204998 | GUANIDINE DEGRADATION ENZYME AND METHODS OF USE - Presented herein are | 2022-06-30 |
20220204999 | PROCESS FOR THE BIOLOGICAL PRODUCTION OF METHACRYLIC ACID AND DERIVATIVES THEREOF - A process of producing methacrylic acid and/or derivatives thereof including the following steps: (a) biologically converting isobutyryl-CoA into methacrylyl-CoA by the action of an oxidase; and (b) converting methacrylyl-CoA into methacrylic acid and/or derivatives thereof. The invention also extends to microorganisms adapted to conduct the steps of the process. | 2022-06-30 |
20220205000 | RECOMBINANT MICROORGANISM INTRODUCED WITH GLUTARIC ACID TRANSPORTER GENE AND METHOD OF PREPARING GLUTARIC ACID USING SAME - The present invention relates to a recombinant microorganism imparted with increased ability to produce glutaric acid by further introducing a gene encoding a polypeptide having glutaric acid transporter activity into a microorganism having ability to produce glutaric acid, and to a method of preparing glutaric acid using the recombinant microorganism. According to the present invention, glutaric acid used for the preparation of various compounds such as polyamide, polyurethane, 1,5-pentanediol, and 5-hydroxyvaleric acid can be biosynthesized at high yield. | 2022-06-30 |
20220205001 | HIGH YIELD LACTIC ACID PRODUCTION USING MIXED CULTURES - The present invention is in the field of a method of producing lactic acid in high yield in a sequencing batch reactor. Therein glucose may be used as feedstock for bacteria, which ferment the glucose into lactic acid. The reactor is operated under at least partly defined non-axenic conditions and in a cyclic mode. | 2022-06-30 |
20220205002 | MUTANT STRAIN HAVING POLYHYDROXYBUTYRATE PRODUCTION ABILITY AND PROCESS FOR PRODUCING POLYHYDROXYBUTYRATE USING THE STRAIN - Disclosed is a mutant strain having the ability to produce polyhydroxybutyrate. The novel strain has a significantly high growth rate and an improved ability to produce PHB compared to existing PHB-producing cyanobacterial strains. Therefore, the novel strain is suitable for use in the production of PHB and the development of various products using PHB. In addition, the novel strain is useful as a photosynthetic strain for developing a PHB production process using industrial flue gas due to its ability to produce PHB from only CO | 2022-06-30 |
20220205003 | MICROORGANISM WITH ENHANCED L-HISTIDINE PRODUCTION CAPACITY AND METHOD FOR PRODUCING HISTIDINE BY USING SAME - Provided are a microorganism having an enhanced L-histidine producing ability and a method of producing histidine using the same. | 2022-06-30 |
20220205004 | COMPOSITIONS AND METHODS FOR MAKING BENZYLISOQUINOLINE ALKALOIDS, MORPHINAN ALKALOIDS, THEBAINE, AND DERIVATIVES THEREOF - Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided. | 2022-06-30 |
20220205005 | METHODS AND SYSTEMS FOR ENZYMATIC HYDROLYSIS OF PRETREATED BIOMASS AT HIGH SOLIDS CONCENTRATIONS - A method of enzymatically hydrolyzing pretreated lignocellulosic biomass at high solids concentration includes introducing pretreated biomass to a hydrolysis reactor, to hydrolyze the cellulose to glucose monomer and glucose oligomers, and circulating a liquid stream, from which glucose is removed to reduce glucose inhibition of cellulose hydrolysis. A surfactant may be added to the hydrolysis reactor. Heat and/or acid treatment of the glucose oligomers may be used to generate additional glucose monomer. Some variations introduce pretreated biomass to a hydrolysis reactor to hydrolyze cellulose to glucose monomer and glucose oligomers, followed by conveying a portion of the solid phase to a mechanical refiner and/or a unit under reduced pressure, to generate a refined and/or exploded solid phase; and recycling the refined and/or exploded solid phase, optionally reheated, back to an input of the hydrolysis reactor. | 2022-06-30 |
20220205006 | Method For Improving Yield Of Sprayed Corn Bran In Corn Wet-Milling Process - Disclosed is a method for improving the yield of sprayed corn bran in a corn wet-milling process, an enzyme preparation is added in the process of separating fiber from starch and protein, the fiber residue after the enzyme preparation treatment contains less water, less starch and/or protein residue, and has a looser and more fluffy structure, the yield of the sprayed corn bran in the corn wet-milling process can be remarkably improved while ensuring normal color of the finished sprayed corn bran, that is, the amount of concentrated corn soaking solution sprayed on the fiber corn bran is significantly increased. | 2022-06-30 |
20220205007 | BIOSYNTHETIC PRODUCTION OF STEVIOL GLYCOSIDE REBAUDIOSIDE I VIA VARIANT ENZYMES - The present invention relates, at least in part, to the production of steviol glycoside rebaudioside I through the use of variant UGT enzymes having activity to transfer a glucosyl group from UDP-glucose to rebaudioside A to produce rebaudioside I. | 2022-06-30 |
20220205008 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates - Provided herein, among other things, is a conjugate comprising a polymerase and a nucleoside triphosphate, where the polymerase and the nucleoside triphosphate are covalently linked via a linker that comprises a cleavable linkage. A set of such conjugates, where the conjugates correspond to G, A, T (or U) and C is also provided. Methods for synthesizing a nucleic acid of a defined sequence are also provided. The conjugates can also be used for sequencing applications. | 2022-06-30 |
20220205009 | MUTATED tRNA FOR CODON EXPANSION - In some embodiments, the present disclosure relates to mutated tRNAs in which the first letter of the anticodon has been substituted to lysidine or agmatidine, and translation systems containing the mutated tRNAs. In a specific embodiment, the present disclosure provides mutated tRNAs capable of selectively translating codon NNA. In another embodiment, the present disclosure provides translation systems capable of translating two or three types of amino acids from a single codon box. In still another embodiment, the present disclosure provides novel methods for synthesizing lysidine diphosphate, agmatidine diphosphate, and derivatives thereof. | 2022-06-30 |
20220205010 | Mogroside Biocatalysis Methods - Monk fruit extracts containing mogrol glycosides such as mogroside V may be treated with enzymes under specific reaction conditions to shift distribution of the Siamenoside I reaction product. Modified enzymes are also employed to shift Siamenoside I distribution to increase yield of Siamenoside I and reduce reaction contaminants. Methods of purifying bioconversion reaction product are also described. Siamenoside I obtained using these methods is a useful sweetener and flavor enhancer for food and beverage compositions and the like. | 2022-06-30 |
20220205011 | METHOD FOR DETECTING PERIODONTOPATHIC BACTERIA - The present invention makes it possible to simply, rapidly, and with high sensitivity detect periodontopathic bacteria at room temperature and in under ten minutes (approximately 2-8 minutes). The arginine-specific peptidase activity of three strains of periodontopathic bacteria, i.e., | 2022-06-30 |
20220205012 | SPECTRAL INTENSITY RATIO (SIR) ANALYSIS FOR RAPID LIVE MICROBIAL ENUMERATION - Single dye fluorescent staining (with a membrane—associated dye such as FM 1-43 or FM 4 -64) and the combination of differences in both intensity and spectral emission discriminate live from inactivated/dead bacteria and provides for rapid and accurate detection of live bacteria in mixed populations. | 2022-06-30 |
20220205013 | APPARATUS AND METHOD FOR DISTINGUISHING ANTIBIOTICS SUSCEPTIBILITY - A method of testing an antibiotic susceptibility includes dispensing and cultivating sample solution into culture wells including one or more comparative wells and a plurality of antibiotic wells receiving two or more kinds of antibiotics, respectively, receiving the sample solution into a plurality of preprocessing wells each including magnetic particles and fluorescent particles that bond to one or more kinds of bacteria such that the bacteria and the magnetic particles and fluorescent particles bond to each other, receiving the sample solution into a plurality of image wells having magnetic members thereunder such that the magnetic particles bonding to the bacteria are arranged on the bottoms of the image wells, removing the sample solution from the image wells that have undergone the planarizing step, taking fluorescent images of the image wells washed in the washing step, and determining an antibiotic tolerance/susceptibility of the sample solution by analyzing the fluorescent images. | 2022-06-30 |
20220205014 | METHOD FOR DETERMINING THE EFFECTIVENESS OF A STERILIZATION METHOD FOR A MEDICAL PRODUCT IN A STERILIZER, DATA PROCESSING SYSTEM, COMPUTER PROGRAM PRODUCT, AND MEDICAL PRODUCT - A process is presented for determining the effectiveness of sterilization processes for medical devices, with the steps of: providing a data structure, wherein the data structure represents a grid formed of a plurality of three-dimensional cells, recreating the medical device arranged in the sterilizer in the data structure in such a way that a first plurality of cells of the grid represent a body of the medical device and that a second plurality of cells represent an interior of the sterilizer which is not occupied by the body of the medical device, recreating an initial state in the data structure in such a way that each cell of the second plurality of cells is assigned data with respect to the temperature prevailing at the location of the cell, the quantity of a first medium located in the area of the cell and the quantity of a second medium located in the area of the cell, recreating, step by step, changes in the temperature, the quantity of the first medium and the quantity of the second medium occurring in each cell of the second plurality of cells during the sterilization process, and calculating a reduction of a germ load achieved in each cell of the second plurality of cells during the sterilization process taking into account the prevailing temperature, quantity of the first medium and quantity of the second medium in the respective cell in each step. Furthermore, a data processing system as well as a computer program product for carrying out the process are presented. | 2022-06-30 |
20220205015 | MEMBRANE PROTEASE-BASED METHODS FOR DETECTION OF BACTERIA - The invention provides a method for detecting bacteria. The method utilises a peptide that forms a complex with a conjugated reporter polymer and is susceptible to cleavage by one or more proteases on the surface of a bacteria. Presence or absence of the bacteria can be determined by assessing the optical absorption and/or colour and/or photoluminescence (e.g. fluorescence) of the conjugated reporter polymer, which may undergo a conformational change after binding with the to the cleaved peptide substrate. Specifically, the peptide substrate may comprise a cleavage site for digestion by the protease, and the protease may be an omptin protease. The conjugated reporter polymer may be selected from a polythiophene, a poly(1,4-phenylene vinylene) (PPV), a poly(1,4-phenylene) (PPP), a polyfluorenes (PFO), a nitrogen-containing polymer such as polyquinoline, poly(2,5-pyridinevinylene) (PPyV), 1,3,4-oxadiazole, and poly(9-vinylcarbazole) (PVK), and a polypyrrole. The method may be used to detect contamination in food or water, or as a clinical and/or diagnostic test. | 2022-06-30 |
20220205016 | Molecular Diagnostic Method Using Cell Lysis Composition For Nucleic Acid Extraction - The present invention relates to a molecular diagnostic method using a cell lysis composition for nucleic acid extraction, and particularly, to a molecular diagnostic method using a cell lysis composition for nucleic acid extraction, which may minimize the time for molecular diagnosis by performing a polymerase chain reaction on a mixture containing both Tween 20 as a component for nucleic acid extraction and a PCR buffer necessary for performing the polymerase chain reaction, without a separate nucleic acid extraction process, and reduce the cost of molecular diagnosis by minimizing the use of dedicated devices and consumables in extraction. | 2022-06-30 |
20220205017 | METHODS AND COMPOSITIONS FOR ENHANCED GENOME COVERAGE AND PRESERVATION OF SPATIAL PROXIMAL CONTIGUITY - Provided herein are methods and compositions for preparing sequencing templates that provide uniform genome coverage and preserve spatial-proximal contiguity information. | 2022-06-30 |
20220205018 | MICROFLUIDIC CHIP ASSEMBLY FOR RAPIDLY PERFORMING DIGITAL POLYMERASE CHAIN REACTION (PCR), AND USE THEREOF - A microfluidic chip assembly for rapidly performing digital polymerase chain reaction (PCR) and use thereof are provided. The microfluidic chip assembly includes at least one microfluidic chip, a heat sink arranged below the microfluidic chip, a heater arranged above the microfluidic chip, a semiconductor cooler arranged between the heat sink and the microfluidic chip, and a heat-conducting plate arranged above the semiconductor cooler. A thin film layer is bonded at the bottom of the microfluidic chip, and the thin film layer abuts against the heat-conducting plate. | 2022-06-30 |
20220205019 | Oscillating Amplification Reaction For Nucleic Acids - One embodiment of the present invention provides for a method for amplifying a template of nucleic acid target sequence contained in a sample. The method includes contacting the sample with an amplification reaction mixture containing a primer complementary to the template of nucleic acid target sequence. A temperature of the reaction is oscillated between an upper temperature and a lower temperature wherein the change in temperature is no greater than about 20° C. during a plurality of temperature cycles. The template of nucleic acid target sequence is amplified. | 2022-06-30 |
20220205020 | COMPOSITIONS AND METHODS FOR DETECTION OF BACTERIA AND FUNGI ASSOCIATED WITH BACTERIAL AND CANDIDA VAGINOSIS - Methods for the rapid detection of the presence or absence of a plurality of Bacterial Vaginosis-related (BV-related) bacteria and/or vulvovaginal candidiasis (VVC)-associated | 2022-06-30 |
20220205021 | Compositions and Methods for Measuring Bacterial Growth - The invention disclosed herein relates generally to the fields of microbiology, ecology and microfluidics. Particularly, the invention disclosed herein provides compositions and methods for isolating bacteria from complex microbial communities and measuring growth rates of the isolated bacteria in a given environmental condition. | 2022-06-30 |